S. A. Bolshakov
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
S. A. Bolshakov has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
- Evgeny Viktorovich Shutov
Botkin Hospital
6 shared publications - Chavdar Savov Pavlov
Botkin Hospital
3 shared publications - Daria A. Teplyuk
Botkin Hospital
3 shared publications - David D. Dolidze
Russian Medical Academy of Continuous Professional Education; S.P. Botkin Moscow Multidisciplinary Scientific and Clinical Centre
3 shared publications - Aleksey V. Shabunin
S.P. Botkin City Clinical Hospital; Russian Medical Academy of Continuous Professional Education of the Ministry of Healthcare of the Russian Federation
2 shared publications - D. V. Slepukhova
Russian Medical Academy for Continuing Professional Education
2 shared publications
Latest Publications
- 29 June 2026
- Published by Russian Dialysis Society in Nephrology and Dialysis
- Vol. 28 (2)
Gut microbiota in patients undergoing hemodialysis and the effect of synbiotic therapy on its composition
Introduction . Growing evidence highlights the critical role of the gut microbiota in human health, homeostasis, and disease development and progression. The gut-kidney axis plays a pivotal role in mediating the interaction between the gut microbiota and renal function. Dysbiosis and progressive biochemical alterations within the intestinal milieu contribute to chronic inflammation and increased intestinal permeability. The systemic translocation of toxic microbial metabolites, particularly uremic toxins, may result in damage to multiple organ systems, including the kidneys. Currently, data on the gut microbiota and its metabolites in patients undergoing hemodialysis, as well as on the effects of symbiotic therapy in this population, remains limited and often conflicting. Methods. The prospective cohort study included 26 patients receiving standard, adequate hemodialysis three times weekly. Gut microbiota samples were collected and analysed at two time points: before initiation of symbiotic therapy, and after months of treatment. Microbial composition was assessed using 16S rRNA sequencing followed by bioinformatic analysis. Results. Synbiotics therapy significantly affected the alpha and beta diversity of the gut microbiota in patients undergoing hemodialysis. Significant changes in alpha-diversity indices were observed following treatment, with decreases in both the Shannon and Chao1 indices. Analysis of beta diversity demonstrated a significant shift in microbial community composition after completion of symbiotic therapy. Specifically, the Bray-Curtis dissimilarity index revealed significant clustering of post-treatment samples. Although baseline microbiota profiles were relatively similar among patients, microbial community dispersion increased substantially following the intervention. Synbiotic therapy was associated with relative abundances of the families Lactobacillaceae and Veillonellaceae, whereas abundancies of the families Anaerovoracaceae and Acidaminococcaceae decreased. These changes were accompanied by reduction in the relative abundance of [Ruminococcus] gnavus, [Ruminococcus] gauvreauii, Phascolarctobacterium, and Sutterella. Conclusion . The observed changes in the gut microbiota composition following symbiotic therapy are complex and difficult to interpret definitely. Nevertheless, we believe that synbiotics administration may promote favorable alternations in the interstinal microbial community. A comprehensive assessment of the clinical significance of these changes should incorporate analyses of circulating metabolites and patient outcomes. Further studies are needed to clarify the effects of synbiotics on the gut microbiota and their potential therapeutic implications in patients undergoing hemodialysis.
- 29 June 2026
- Published by Russian Dialysis Society in Nephrology and Dialysis
- Vol. 28 (2)
Gut microbiota in patients undergoing hemodialysis and the effect of synbiotic therapy on its composition
Introduction . Growing evidence highlights the critical role of the gut microbiota in human health, homeostasis, and disease development and progression. The gut-kidney axis plays a pivotal role in mediating the interaction between the gut microbiota and renal function. Dysbiosis and progressive biochemical alterations within the intestinal milieu contribute to chronic inflammation and increased intestinal permeability. The systemic translocation of toxic microbial metabolites, particularly uremic toxins, may result in damage to multiple organ systems, including the kidneys. Currently, data on the gut microbiota and its metabolites in patients undergoing hemodialysis, as well as on the effects of symbiotic therapy in this population, remains limited and often conflicting. Methods. The prospective cohort study included 26 patients receiving standard, adequate hemodialysis three times weekly. Gut microbiota samples were collected and analysed at two time points: before initiation of symbiotic therapy, and after months of treatment. Microbial composition was assessed using 16S rRNA sequencing followed by bioinformatic analysis. Results. Synbiotics therapy significantly affected the alpha and beta diversity of the gut microbiota in patients undergoing hemodialysis. Significant changes in alpha-diversity indices were observed following treatment, with decreases in both the Shannon and Chao1 indices. Analysis of beta diversity demonstrated a significant shift in microbial community composition after completion of symbiotic therapy. Specifically, the Bray-Curtis dissimilarity index revealed significant clustering of post-treatment samples. Although baseline microbiota profiles were relatively similar among patients, microbial community dispersion increased substantially following the intervention. Synbiotic therapy was associated with relative abundances of the families Lactobacillaceae and Veillonellaceae, whereas abundancies of the families Anaerovoracaceae and Acidaminococcaceae decreased. These changes were accompanied by reduction in the relative abundance of [Ruminococcus] gnavus, [Ruminococcus] gauvreauii, Phascolarctobacterium, and Sutterella. Conclusion . The observed changes in the gut microbiota composition following symbiotic therapy are complex and difficult to interpret definitely. Nevertheless, we believe that synbiotics administration may promote favorable alternations in the interstinal microbial community. A comprehensive assessment of the clinical significance of these changes should incorporate analyses of circulating metabolites and patient outcomes. Further studies are needed to clarify the effects of synbiotics on the gut microbiota and their potential therapeutic implications in patients undergoing hemodialysis.
- Open Access
- 10 December 2024
- Published by LLC Global Media Technology in Experimental and Clinical Gastroenterology
- No. 10,p. 178-187
The gut microbiome and nonalcoholic fatty liver disease: prospects for drug therapy
Nonalcoholic fatty liver disease (NAFLD) is most commonly a component of the metabolic syndrome with a global prevalence of 25% and the number of patients continues to increase. According to current projections, in the near future, NAFLD will become the most common indication for liver transplantation. The search for new risk factors for the development and progression of this disease is actively underway. The article considers the role of intestinal microbiota in proinflammatory processes, bile acid metabolism and liver lipogenesis. Attention is paid to the qualitative composition of the microbiome depending on the stage of NAFLD. Conclusions are made about heterogeneity of the research results in case of NAFLD and relatively stable microbiota in liver cirrhosis. Faecalibacterium prausnitzii and its role in the progression of NAFLD are considered separately. Probable reasons for the disagreement of the results of the studies are presented. In the part devoted to the treatment of NAFLD, the focus is on the ways of correction of intestinal dysbiosis, the influence of various microbiological preparations on lipogenesis and the process of inflammation in the liver. The optimal composition of probiotic preparations is discussed in detail. Their combination with prebiotics and isolated administration of inulin, fructooligosaccharide. Conclusions are drawn that in the future the assessment of intestinal microbiome will help to improve therapeutic approaches in the treatment of NAFLD patients.
- 10 December 2024
- Published by LLC Global Media Technology in Experimental and Clinical Gastroenterology
- No. 10,p. 178-187
Open AccessThe gut microbiome and nonalcoholic fatty liver disease: prospects for drug therapy
Nonalcoholic fatty liver disease (NAFLD) is most commonly a component of the metabolic syndrome with a global prevalence of 25% and the number of patients continues to increase. According to current projections, in the near future, NAFLD will become the most common indication for liver transplantation. The search for new risk factors for the development and progression of this disease is actively underway. The article considers the role of intestinal microbiota in proinflammatory processes, bile acid metabolism and liver lipogenesis. Attention is paid to the qualitative composition of the microbiome depending on the stage of NAFLD. Conclusions are made about heterogeneity of the research results in case of NAFLD and relatively stable microbiota in liver cirrhosis. Faecalibacterium prausnitzii and its role in the progression of NAFLD are considered separately. Probable reasons for the disagreement of the results of the studies are presented. In the part devoted to the treatment of NAFLD, the focus is on the ways of correction of intestinal dysbiosis, the influence of various microbiological preparations on lipogenesis and the process of inflammation in the liver. The optimal composition of probiotic preparations is discussed in detail. Their combination with prebiotics and isolated administration of inulin, fructooligosaccharide. Conclusions are drawn that in the future the assessment of intestinal microbiome will help to improve therapeutic approaches in the treatment of NAFLD patients.
- Open Access
- 20 September 2024
- Published by Russian Dialysis Society in Nephrology and Dialysis
- Vol. 26 (3) , 283-302
Gut microbiota and kidney diseases. Literature review
Recent technological advances have significantly enhanced our understanding of the role microbial communities play in the human body. The gut microbiota, one of the most diverse microbiomes, consists of over 35,000 bacterial species and 10 million genes, leading researchers to consider it as an additional organ. This whiles relatively stable within each individual highly influenced by exogenous and endogenous factors. Collectively, the gut microbiota functions as a "second genome", profoundly impacting the host’s metabolic pathways and regulating the body’s complex homeostatic balance.Research into the "microbe–host" interaction, both in health and disease, has garnered worldwide scientific. In chronic kidney disease (CKD), the gut microbiota undergoes significant changes, and growing evidences suggests that dysbiosis plays a crucial role in the progression of renal failure. Key pathological process, such as the production of gut-derived uremic toxins, decreased synthesis of short– chain fatty acids, altered intestinal pH, compromised intestinal barrier function, and heightened systemic inflammation, are all linked the intestinal microbiota. However, relationship between these changes and the pathogenesis and progression of kidney disease requires further investigation. Advances in microbiome research, including metagenomic and metatranscriptomic analyses, alongside proteomic, metabolomics, and immunomic studies, have greatly expanded our understanding of microbiomal community structure and functions. These technologies, coupled with mechanistic experiments in model systems, have deepened our knowledge of how the microbiome influences metabolism. Current research aims to explore the bidirectional relationship between the microbiota and the host, identifying potential interventions that could help restore a mutualistic relationship.
- 20 September 2024
- Published by Russian Dialysis Society in Nephrology and Dialysis
- Vol. 26 (3) , 283-302
Open AccessGut microbiota and kidney diseases. Literature review
Recent technological advances have significantly enhanced our understanding of the role microbial communities play in the human body. The gut microbiota, one of the most diverse microbiomes, consists of over 35,000 bacterial species and 10 million genes, leading researchers to consider it as an additional organ. This whiles relatively stable within each individual highly influenced by exogenous and endogenous factors. Collectively, the gut microbiota functions as a "second genome", profoundly impacting the host’s metabolic pathways and regulating the body’s complex homeostatic balance.Research into the "microbe–host" interaction, both in health and disease, has garnered worldwide scientific. In chronic kidney disease (CKD), the gut microbiota undergoes significant changes, and growing evidences suggests that dysbiosis plays a crucial role in the progression of renal failure. Key pathological process, such as the production of gut-derived uremic toxins, decreased synthesis of short– chain fatty acids, altered intestinal pH, compromised intestinal barrier function, and heightened systemic inflammation, are all linked the intestinal microbiota. However, relationship between these changes and the pathogenesis and progression of kidney disease requires further investigation. Advances in microbiome research, including metagenomic and metatranscriptomic analyses, alongside proteomic, metabolomics, and immunomic studies, have greatly expanded our understanding of microbiomal community structure and functions. These technologies, coupled with mechanistic experiments in model systems, have deepened our knowledge of how the microbiome influences metabolism. Current research aims to explore the bidirectional relationship between the microbiota and the host, identifying potential interventions that could help restore a mutualistic relationship.
- 1 January 2023
- Published by Russian Dialysis Society in Nephrology and Dialysis
- Vol. 25 (2)
Secondary hyperparathyroidism. Specific features, complexity, features of treatment. Literature review. Part I
- 1 January 2023
- Published by Russian Dialysis Society in Nephrology and Dialysis
- Vol. 25 (2)
Secondary hyperparathyroidism. Specific features, complexity, features of treatment. Literature review. Part I
- 26 September 2022
- Published by Bionika Media in Nephrology
- Vol. 3_2022
Evaluation of humoral response to Gam-Covid-Vac (Sputnik V) vaccination against COVID-19 in patients on hemodialysis and peritoneal dialysis
- 26 September 2022
- Published by Bionika Media in Nephrology
- Vol. 3_2022
Evaluation of humoral response to Gam-Covid-Vac (Sputnik V) vaccination against COVID-19 in patients on hemodialysis and peritoneal dialysis
- Open Access
- 25 October 2021
- Published by Sechenov University in Sechenov Medical Journal
- Vol. 13 (1) , 34-42
DRESS syndrome on the background of adding meropenem to carbamazepine therapy: a clinical case
DRESS syndrome on the background of adding meropenem to carbamazepine therapy: a clinical case
- 25 October 2021
- Published by Sechenov University in Sechenov Medical Journal
- Vol. 13 (1) , 34-42
Open AccessDRESS syndrome on the background of adding meropenem to carbamazepine therapy: a clinical case
DRESS syndrome on the background of adding meropenem to carbamazepine therapy: a clinical case